Table S1. Clinical and Sociodemographic Characteristics of Full Sample.
| Drug Class | ||||||||||||
| Antipsychotic (N = 96) |
SNRI (N = 409) |
SSRI (N = 430) |
TCA (N = 38) |
Other AD (N = 399) |
Total (N = 1032) |
|||||||
| Age (years) | ||||||||||||
| Mean (SD) | 49.1 (12.8) | 49.1 (14.3) | 47.2 (14.9) | 51.8 (14.1) | 47.8 (14.4) | 48.0 (14.5) | ||||||
| Median | 53.0 | 51.0 | 49.0 | 54.0 | 50.0 | 50.0 | ||||||
| Min, Max | 18, 74 | 18, 83 | 18, 90 | 23, 73 | 18, 85 | 18, 90 | ||||||
| Age Group, N(%) | ||||||||||||
| 18 to 34 | 15 (15.6) | 80 (19.6) | 103 (24.0) | 7 (18.4) | 90 (22.6) | 227 (22.0) | ||||||
| 35 to 49 | 23 (24.0) | 115 (28.1) | 119 (27.7) | 6 (15.8) | 109 (27.3) | 285 (27.6) | ||||||
| 50 to 64 | 49 (51.0) | 154 (37.7) | 151 (35.1) | 16 (42.1) | 146 (36.6) | 379 (36.7) | ||||||
| 65 and Over | 9 (9.4) | 60 (14.7) | 57 (13.3) | 9 (23.7) | 54 (13.5) | 141 (13.7) | ||||||
| Sex, N(%) | ||||||||||||
| Female | 71 (74.0) | 296 (72.4) | 297 (69.1) | 26 (68.4) | 277 (69.4) | 728 (70.5) | ||||||
| Male | 25 (26.0) | 113 (27.6) | 133 (30.9) | 12 (31.6) | 122 (30.6) | 304 (29.5) | ||||||
| Ethnicity, N(%) | ||||||||||||
| Hispanic or Latino | 8 (8.3) | 33 (8.1) | 39 (9.1) | 2 (5.3) | 19 (4.8) | 80 (7.8) | ||||||
| Not Hispanic or Latino | 88 (91.7) | 376 (91.9) | 391 (90.9) | 36 (94.7) | 380 (95.2) | 952 (92.2) | ||||||
| Race, N(%) | ||||||||||||
| White | 78 (81.3) | 347 (84.8) | 333 (77.4) | 34 (89.5) | 327 (82.0) | 838 (81.2) | ||||||
| Black | 16 (16.7) | 45 (11.0) | 78 (18.1) | 2 (5.3) | 57 (14.3) | 151 (14.6) | ||||||
| Asian | 0 | 7 (1.7) | 9 (2.1) | 1 (2.6) | 9 (2.3) | 19 (1.8) | ||||||
| Other or Multiple | 2 (2.1) | 10 (2.4) | 10 (2.3) | 1 (2.6) | 6 (1.5) | 24 (2.3) | ||||||
| Annual Income ($), N(%) | ||||||||||||
| 0–25,000 | 46 (47.9) | 174 (42.5) | 198 (46.0) | 7 (18.4) | 176 (44.1) | 442 (42.8) | ||||||
| 25,000–50,000 | 21 (21.9) | 94 (23.0) | 105 (24.4) | 17 (44.7) | 104 (26.1) | 253 (24.5) | ||||||
| 50,000–75,000 | 8 (8.3) | 53 (13.0) | 45 (10.5) | 6 (15.8) | 38 (9.5) | 117 (11.3) | ||||||
| 75,000–100,000 | 10 (10.4) | 20 (4.9) | 7 (4.0) | 1 (2.6) | 26 (6.5) | 52 (5.0) | ||||||
| 100,000 and above | 2 (2.1) | 19 (4.6) | 7 (1.6) | 3 (7.9) | 13 (3.3) | 35 (3.4) | ||||||
| Refused to answer | 9 (9.4) | 49 (12.0) | 58 (13.5) | 4 (10.5) | 42 (10.5) | 133 (12.9) | ||||||
| Highest Level of Education, N(%) | ||||||||||||
| Less than high school | 5 (5.2) | 13 (3.3) | 18 (4.2) | 1 (2.7) | 14 (3.5) | 34 (3.3) | ||||||
| High school diploma or equivalent | 15 (15.6) | 66 (16.5) | 103 (24.3) | 6 (16.2) | 80 (20.3) | 212 (20.9) | ||||||
| Some college or postsecondary, no degree | 25 (26.0) | 100 (25.0) | 106 (25.0) | 8 (21.6) | 110 (27.8) | 252 (24.8) | ||||||
| Associate’s degree | 14 (14.6) | 60 (15.0) | 42 (9.9) | 2 (5.4) | 50 (12.7) | 128 (12.6) | ||||||
| Bachelor’s degree | 20 (20.8) | 99 (24.8) | 103 (24.3) | 12 (32.4) | 94 (23.8) | 246 (24.2) | ||||||
| Master’s degree | 12 (12.5) | 47 (11.8) | 43 (10.1) | 7 (18.9) | 30 (7.6) | 109 (10.7) | ||||||
| Doctoral or professional degree | 5 (5.2) | 15 (3.8) | 9 (2.1) | 1 (2.7) | 17 (4.3) | 34 (3.3) | ||||||
| Smoker, N(%) | ||||||||||||
| No | 79 (82.3) | 347 (84.8) | 356 (82.8) | 31 (81.6) | 344 (86.2) | 872 (84.5) | ||||||
| Yes | 17 (17.7) | 62 (15.2) | 74 (17.2) | 7 (18.4) | 55 (13.8) | 160 (15.5) | ||||||
| Generalized Anxiety Disorder Diagnosis, N(%) | ||||||||||||
| 0 | 71 (74.0) | 326 (79.7) | 367 (85.5) | 31 (81.6) | 330 (82.9) | 864 (83.8) | ||||||
| 1 | 25 (26.0) | 83 (20.3) | 62 (14.5) | 7 (18.4) | 68 (17.1) | 167 (16.2) | ||||||
| Panic Disorder, Diagnosis, N(%) | ||||||||||||
| 0 | 68 (70.8) | 337 (82.4) | 366 (85.3) | 33 (86.8) | 334 (83.9) | 873 (84.7) | ||||||
| 1 | 28 (29.2) | 72 (17.6) | 63 (14.7) | 5 (13.2) | 64 (16.1) | 158 (15.3) | ||||||
| Posttraumatic Stress Disorder Diagnosis, N(%) | ||||||||||||
| 0 | 87 (90.6) | 382 (93.4) | 413 (96.3) | 36 (94.7) | 379 (95.2) | 980 (95.1) | ||||||
| 1 | 9 (9.4) | 27 (6.6) | 16 (3.7) | 2 (5.3) | 19 (4.8) | 51 (4.9) | ||||||
| Drug Class | ||||||||||||
| Antipsychotic (N = 96) |
SNRI (N = 409) |
SSRI (N = 430) |
TCA (N = 38) |
Other AD (N = 399) |
Total (N = 1032) |
|||||||
| Depression Category, N (%) | ||||||||||||
| Moderate (HAM-D17 14–18) | 16 (16.7) | 111 (27.1) | 134 (31.2) | 9 (23.7) | 102 (25.6) | 289 (28.0) | ||||||
| Severe (HAM-D17 19–22) | 43 (44.8) | 145 (35.5) | 155 (36.0) | 13 (34.2) | 152 (38.1) | 373 (36.1) | ||||||
| Very Severe (HAM-D17 > 23) | 37 (38.5) | 153 (37.4) | 141 (32.8) | 16 (42.1) | 145 (36.3) | 370 (35.9) | ||||||
| Baseline HAM-D17 | ||||||||||||
| Mean (SD) | 21.9 (3.7) | 21.3 (4.2) | 21.0 (4.3) | 21.4 (4.0) | 21.3 (4.1) | 21.2 (4.2) | ||||||
| Median | 21.0 | 21.0 | 21.0 | 21.0 | 21.0 | 21.0 | ||||||
| Min, Max | 15, 33 | 14, 35 | 14, 37 | 14, 30 | 14, 35 | 14, 37 | ||||||
| Number of Medication Trials Without Response | ||||||||||||
| Mean (SD) | 4.5 (3.0) | 3.1 (2.2) | 2.8 (2.1) | 4.2 (3.1) | 3.3 (2.5) | 3.0 (2.3) | ||||||
| Median | 4.0 | 2.0 | 2.0 | 3.0 | 3.0 | 2.0 | ||||||
| Min, Max | 1, 18 | 1, 16 | 1, 18 | 1, 13 | 1, 18 | 1, 18 | ||||||
| Number of Comorbidities | ||||||||||||
| Mean (SD) | 8.3 (6.4) | 7.5 (5.6) | 7.0 (5.4) | 8.2 (4.5) | 6.8 (5.5) | 7.0 (5.5) | ||||||
| Median | 7.0 | 6.0 | 6.0 | 8.0 | 6.0 | 6.0 | ||||||
| Min, Max | 1, 45 | 0, 47 | 0, 38 | 0, 21 | 0, 45 | 0, 47 | ||||||
| Baseline Weight (pounds) | ||||||||||||
| Mean (SD) | 197.2 (41.8) | 196.3 (49.8) | 193.2 (49.1) | 182.4 (48.1) | 192.4 (48.4) | 193.3 (49.8) | ||||||
| Median | 191.2 | 191.8 | 185.2 | 177.9 | 185.5 | 186.0 | ||||||
| Min, Max | 112, 320 | 98, 363 | 102, 387 | 108, 300 | 95, 380 | 95, 387 | ||||||
The following table details a variety of features for the full sample used in this analysis stratified by five broad medication classes (n = 1032). These strata are not mutually exclusive. For example, someone on both a selective serotonin reuptake inhibitor and an antipsychotic would be included in both relevant columns.
Snri = serotonin-norepinephrine reuptake inhibitor, ssri = selective serotonin reuptake inhibitor, tca = tricyclic antidepressant, ad = antidepressan.